- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05057936
Antibody After COVID-19 Vaccination
Antibody Response After COVID-19 Vaccination in Chronic Kidney Disease and Kidney Transplant Patients
Chronic kidney disease (CKD) including patients on dialysis and kidney transplant recipients. represents the special subgroups of patients that required protection during the Severe Coronavirus Disease 2019 (COVID-19) pandemic .Since COVID-19 is associated with severe morbidity and mortality in these particular subgroup of patients, the main strategies is proper and rapid vaccination. CKD patients usually have a reduced immune responses, vaccination in these group of patients usually require higher dosage and more frequent dose since the vaccine response is short-lived and less response especially in dialysis patients5 .In patients with normal renal function,the immunity is durable but with modest declines at 6-8months. One study showed a linear decline in IgG in dialysis patients for up to 3months , but there are otherwise limited data.
Previous reports of the vaccination in CKD patient involved mainly the mRNA vaccines. The recent reports of seroconversion rate dialysis patients receiving two doses of BNT 162b2 vaccine (Pfizer BioNtech) was lower than in control. In Thailand, the main vaccines available are Coronavac (Sinovac Life Science, Beijing, China) and ChadOx1 nCoV-19 (Oxford-Astra Zeneca) which was dispensed all over the country since April 2021. Data of the efficacy and safety of these vaccines in these patient groups is lacking. Therefore, the aim of this study is to measure the antibody and cellular responses in CKD patients including those with dialysis therapy and kidney transplantation and monitor the adverse events after the first and second doses of after vaccination. The incidence rate of Sars-COV2 infection post vaccination was also observed.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Bangkok, Thailand, 10300
- Faculty of Medicine,Vajira Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- CKD stage 3-5 (eGFR < 60 mL/min/1.73m3)
- CKD stage 5 patients receiving HD,CAPD and KT for more than 3 months.
- The participants of the healthy control group consists of volunteer health care workers who had been vaccinated according to the nation vaccination schedule
Exclusion Criteria:
- allergy to the components of vaccines
- unable to receive the vaccine according to the schedule
- fever or concomitant serious illnesses
- had side effect from the first dose of vaccination
- prior COVID-19 infection in the past (diagnosed via patients history and serological test for nucleocapsid (NCP) antibody
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Control
Healthy healthcare workers
|
The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study.
All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
|
Chronic kidney disease (CKD)
CKD stage 3-5 (eGFR < 60 mL/min/1.73m3)
|
The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study.
All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
|
Dialysis patients
CKD stage 5 requiring HD
|
The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study.
All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
|
kidney transplant patients
patients receiving kidney transplantation for more than 3 months
|
The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study.
All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
|
dialysis patients
CKD patients requring continuos ambulatory peritoneal dialysis
|
The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study.
All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Immunogenicity after COVID-19 vaccination
Tidsramme: Baseline before vaccination
|
levels of SARS-CoV2 spike S1-specific immunoglobulin (IgG) antibody concentration
|
Baseline before vaccination
|
Immunogenicity after COVID-19 vaccination
Tidsramme: The second dose of vaccination
|
levels of SARS-CoV2 spike S1-specific immunoglobulin (IgG) antibody concentration
|
The second dose of vaccination
|
Immunogenicity after COVID-19 vaccination
Tidsramme: Eight weeks after the second dose of vaccination
|
levels of SARS-CoV2 spike S1-specific immunoglobulin (IgG) antibody concentration
|
Eight weeks after the second dose of vaccination
|
Immunogenicity after COVID-19 vaccination
Tidsramme: Baseline before vaccination
|
Viral neutralization test measured by surrogate virus neutralization test (SVNT)
|
Baseline before vaccination
|
Immunogenicity after COVID-19 vaccination
Tidsramme: The second dose of vaccination
|
Viral neutralization test measured by surrogate virus neutralization test (SVNT)
|
The second dose of vaccination
|
Immunogenicity after COVID-19 vaccination
Tidsramme: Eight weeks after the second dose of vaccination
|
Viral neutralization test measured by surrogate virus neutralization test (SVNT)
|
Eight weeks after the second dose of vaccination
|
Immunogenicity after COVID-19 vaccination
Tidsramme: Baseline before vaccination
|
Cellular immunity by interferon gamma level
|
Baseline before vaccination
|
Immunogenicity after COVID-19 vaccination
Tidsramme: The second dose of vaccination
|
Cellular immunity by interferon gamma level
|
The second dose of vaccination
|
Immunogenicity after COVID-19 vaccination
Tidsramme: Eight weeks after the second dose of vaccination
|
Cellular immunity by interferon gamma level
|
Eight weeks after the second dose of vaccination
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
rates of adverse events after vaccination
Tidsramme: 28 days
|
drug allergy ,skin rash,liver toxicity
|
28 days
|
the incidence of COVID-19 breakthrough infection after vaccination
Tidsramme: 28 days
|
number of cases that develop COVID-19 infection after vaccination
|
28 days
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum In: Lancet. 2020 Aug 15;396(10249):466. Lancet. 2020 Dec 12;396(10266):1884.
- Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, Kieneker LM, Noordzij M, Pena MJ, Vries H, Arroyo D, Covic A, Crespo M, Goffin E, Islam M, Massy ZA, Montero N, Oliveira JP, Roca Munoz A, Sanchez JE, Sridharan S, Winzeler R, Gansevoort RT; ERACODA Collaborators. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983. doi: 10.1093/ndt/gfaa261. Erratum In: Nephrol Dial Transplant. 2021 Feb 24;:
- Kengibe PY, Makulo JR, Nlandu YM, Lepira FB, Sumaili EK, Bukabau JB, Mbendi CN, Ahuka SM, Tshimpi AW, Ngoma PK, Mangani NN, Mbendi SN. Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study. Pan Afr Med J. 2019 Oct 31;34:122. doi: 10.11604/pamj.2019.34.122.19603. eCollection 2019.
- Bensouna I, Caudwell V, Kubab S, Acquaviva S, Pardon A, Vittoz N, Bozman DF, Hanafi L, Faucon AL, Housset P. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis. Am J Kidney Dis. 2022 Feb;79(2):185-192.e1. doi: 10.1053/j.ajkd.2021.08.005. Epub 2021 Sep 8.
- Carr EJ, Kronbichler A, Graham-Brown M, Abra G, Argyropoulos C, Harper L, Lerma EV, Suri RS, Topf J, Willicombe M, Hiremath S. Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD. Kidney Int Rep. 2021 Sep;6(9):2292-2304. doi: 10.1016/j.ekir.2021.06.027. Epub 2021 Jul 6.
- Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, Rechavi Y, Schwartz IF, Schwartz D, Lellouch Y, Shashar M. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2021 Jul;16(7):1037-1042. doi: 10.2215/CJN.03500321. Epub 2021 Apr 6.
- Labriola L, Scohy A, Seghers F, Perlot Q, De Greef J, Desmet C, Romain C, Morelle J, Yombi JC, Kabamba B, Rodriguez-Villalobos H, Jadoul M. A Longitudinal, 3-Month Serologic Assessment of SARS-CoV-2 Infections in a Belgian Hemodialysis Facility. Clin J Am Soc Nephrol. 2021 Apr 7;16(4):613-614. doi: 10.2215/CJN.12490720. Epub 2020 Nov 18. No abstract available.
- Ikizler TA, Coates PT, Rovin BH, Ronco P. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney Int. 2021 Jun;99(6):1275-1279. doi: 10.1016/j.kint.2021.04.007. Epub 2021 Apr 20.
- Torreggiani M, Blanchi S, Fois A, Fessi H, Piccoli GB. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int. 2021 Jun;99(6):1494-1496. doi: 10.1016/j.kint.2021.04.010. Epub 2021 Apr 20. No abstract available.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 101/64
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Covid-19
-
HealthQuiltFullførtImmunfunksjon | Covid19 positiv pasient | Covid19 nærkontaktForente stater
-
VA Office of Research and DevelopmentAktiv, ikke rekrutterendeKOLS-pasienter og pasienter som kommer seg etter COVID19Forente stater
-
Bahçeşehir UniversityFullførtLang Covid19 | Autonom dysfunksjonTyrkia
-
Ohio State UniversityRekrutteringPost-akutt COVID19-syndrom | Lang COVID | Tilstand etter COVID19Forente stater
-
Texas Woman's UniversityNational Institutes of Health (NIH)Har ikke rekruttert ennå
-
Aarhus University HospitalUniversity of Aarhus; Pharma NordFullført
-
Cairo UniversityKasr El Aini HospitalUkjentCOVID19 lungebetennelseEgypt
-
Assistance Publique - Hôpitaux de ParisUkjent
-
Saglik Bilimleri Universitesi Gazi Yasargil Training...FullførtCovid19 og dødelighetTyrkia
-
Brugmann University HospitalRekruttering
Kliniske studier på COVID vaccine
-
TASK Applied ScienceFullført
-
Direction Centrale du Service de Santé des ArméesFullførtCovid-19 | SARS-CoV2-infeksjonFrankrike
-
EyeGene Inc.Novotech (Australia) Pty LimitedAktiv, ikke rekrutterende
-
AstraZenecaFullførtCovid-19Storbritannia
-
King's College LondonGuy's and St Thomas' NHS Foundation Trust; UK Research and InnovationRekrutteringCovid-19 | Periodontale sykdommer | Mikrobiell kolonisering | Oral sykdom | Slimhinneinfeksjon | Medfødt inflammatorisk responsStorbritannia
-
Melike CengizFullført
-
University of PennsylvaniaPublic Health Management CorporationFullført
-
Hasanuddin UniversityChulalongkorn UniversityFullført
-
University of PennsylvaniaPublic Health Management CorporationFullført
-
Gailen D. Marshall Jr., MD PhDUniversity of Mississippi Medical CenterFullført